Dec. 3 at 2:51 PM
$ONTTF
Oxford Nanopore is going into the FTSE 250 according to FTSE Russell.
They have also announced a partnership with UK Biobank for an "epigenetic dataset targeting the causes of cancer, dementia, complex disease." Financial backers of Biobank include Eric Schmidt and Ken Griffin. No impact on 2024, but supports the incremental revenue growth target of over 30% constant growth y-on-y between 2024 and 2027.